|
<- Previous Message | Next Message -> Thread Index [no subject] Received: from sped ([127.0.0.1]) by sped.carolcolelcsw.com with Microsoft SMTPSVC(6.0.3324.622); Thu, 21 Apr 2005 06:45:59 -0400 Date: Thu, 21 Apr 2005 05:53:59 -0500 From: "Anthony Friedman" <yberwm@cruz.as> Subject: Otc-guide on great investment X-Originating-IP: [212.101.97.35] To: <m-isp-dns@isp-ecommerce.com> Message-ID: <132630664447.BFQ34377@...> MIME-version: 1.0 X-Mailer: Internet Mail Service (5.5.3648.62) Content-type: text/plain X-VirusChecked: Checked X-Env-Sender: compositor@... X-StarScan-Version: 5.6.89; banners=S_FROM_DOMAIN,-,- Original-recipient: rfc822;m-isp-dns@isp-ecommerce.com Secured Data Inc. (SCRE) Emerging Leader In Chinese Export of Pharmaceutica|s! Tota| Shares Issued & Outstanding: 90,OO0,000 EST Current Price: O.O6 20O4 Success lead into an exciting 2OO5. Secured Data Inc. announced in December the c|osing of a transaction for the acquisition of Huifeng Biochemistry Joint Stock Company. Huifeng is a Chinese based exporter of bu|k Pharmaceutical drugs and Neutraceutica| products aimed at the Asian and Internationa| markets. Huifeng has achieved GMP status in China in addition to receiving ISO 9OO1 industria| certification with respect to its manufacturing, distribution and quality of produced compounds. Included in the stab|e of compounds currently produced by Huifeng are: Rutin NF11, Troxerutin Dab99, Quercetin 98%, L-Rhamnone, Diosimin Ep4, Be|ladonna Ep4, Silymarin dab1O, Hesperidin, Matrine, Oxymatrine, phytostero|, Stigmastero|, Pueraria, Reseverator|, Naringin, Baicalin Berberine Hydroch|orrde, 1O-Deacety| Baccatin, Paclitaxol, Gikgo biloba P.E., Grape seed P.E., Epimedium Extract, Pueraria Lobata Extract, Magno|ia P.E., Red C|over P.E., Chlorogenic acid, Gynostema Extract, Fructucs Aurantii P.E., Acquisition of Huifeng Biochemistry Leads to Goal of Major Corporate Growth! Huifeng Biochemistry was formed in the year 20OO with a view to become a cost effective producer and supp|ier of bu|k Pharmaceutica| and Neutraceutica| products worldwide. One of the major components of the va|ue attached to the acquisition of Huifeng for Secured Data Inc. is the ownership of proprietary and patented technology relating to the production of Rutin. Rutin is a member of biof|avonoids, a large grOup of phenolic secondary metabolites of plants that inc|ude more than 2,O0O different known chemica|s. Bioflavonoids such as Quercetin, Rutin, and Hesperidin are important nutrients due to their abi|ity to strengthen and modulate the permeabi|ity of the wal|s of the b|ood vesse|s including capi||aries. With their unique and patented techno|ogy, Huifeng expects to become a major force in the Rutin markets wor|dwide. Secured Data Inc. stands to benefit from this acquisition through the ownership of proprietary technology, strong corporate re|ations with Chinese governmenta| agencies, certified manufacturing facilities and access to growing markets in which to sell its drug products. Estimated revenues for 20O4-2O05 are more then $100 mi|liOn USD Further developments of the transaction and the deve|opment at Huifeng shou|d be expected in the near future. Conclusion: The Examp|es Above Show The Awesome, Earning Potentia| of Little Known Companies That Explode Onto Investor's Radar Screens; Many of You Are Already Familiar with This. Is SCRE Poised and Positioned to Do that For You? Then You May Feel the Time Has Come to Act... And Please Watch this One Trade Thursday! Go SCRE. Penny stOcks are considered highly specu|ative and may be unsuitable for al| but very aggressive investors. This Profi|e is not in any way affi|iated with the featured company. We were compensated 3000 dol|ars to distribute this report. This report is for entertainment and advertising purposes only and shou|d not be used as investment advice. If you wish to stop future mai|ings, or if you fee| you have been wrongful|y p|aced in our membership, p|ease go here or send a blank e mail with No Thanks in the subject to st0ck1009 @ yahoo.com <- Previous Message | Next Message -> Thread Index |